Rigel Pharmaceuticals (NASDAQ:RIGL) and Roivant Sciences (NASDAQ:ROIV) Head to Head Contrast

Rigel Pharmaceuticals (NASDAQ:RIGL) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Insider and Institutional Ownership

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Rigel Pharmaceuticals and Roivant Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	106.59%	14.89%	11.99%
Roivant Sciences	-838.21%	-22.03%	-20.55%

Valuation & Earnings

This table compares Rigel Pharmaceuticals and Roivant Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28 million	2.81	$367.02 million	$15.51	2.83
Roivant Sciences	$8.26 million	3,601.98	-$299.77 million	($0.53)	-77.72

Rigel Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Rigel Pharmaceuticals and Roivant Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1	2	3	0	2.33
Roivant Sciences	1	2	10	1	2.79

Rigel Pharmaceuticals presently has a consensus target price of $66.75, indicating a potential upside of 52.02%. Roivant Sciences has a consensus target price of $46.64, indicating a potential upside of 13.22%. Given Rigel Pharmaceuticals’ higher probable upside, equities research analysts plainly believe Rigel Pharmaceuticals is more favorable than Roivant Sciences.

Volatility and Risk

Rigel Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Summary

Rigel Pharmaceuticals beats Roivant Sciences on 10 of the 14 factors compared between the two stocks.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.